Expression of follicle-stimulating hormone receptor in tumor blood vessels
- PMID: 20961245
- DOI: 10.1056/NEJMoa1001283
Expression of follicle-stimulating hormone receptor in tumor blood vessels
Abstract
Background: In adult humans, the follicle-stimulating hormone (FSH) receptor is expressed only in the granulosa cells of the ovary and the Sertoli cells of the testis. It is minimally expressed by the endothelial cells of gonadal blood vessels.
Methods: We used immunohistochemical and immunoblotting techniques involving four separate FSH-receptor-specific monoclonal antibodies that recognize different FSH receptor epitopes and in situ hybridization to detect FSH receptor in tissue samples from patients with a wide range of tumors. Immunoelectron microscopy was used to detect FSH receptor in mouse tumors.
Results: In all 1336 patients examined, FSH receptor was expressed by endothelial cells in tumors of all grades, including early T1 tumors. The tumors were located in the prostate, breast, colon, pancreas, urinary bladder, kidney, lung, liver, stomach, testis, and ovary. In specimens obtained during surgery performed to remove tumors, the FSH receptor was not expressed in the normal tissues located more than 10 mm from the tumors. The tumor lymphatic vessels did not express FSH receptor. The endothelial cells that expressed FSH receptor were located at the periphery of the tumors in a layer that was approximately 10 mm thick; this layer extended both into and outside of the tumor. Immunoelectron microscopy in mice with xenograft tumors, after perfusion with anti–FSH-receptor antibodies coupled to colloidal gold, showed that the FSH receptor is exposed on the luminal endothelial surface and can bind and internalize circulating ligands.
Conclusions: FSH receptor is selectively expressed on the surface of the blood vessels of a wide range of tumors. (Funded by INSERM.).
Similar articles
-
Expression and cellular localization of follicle-stimulating hormone receptor in normal human prostate, benign prostatic hyperplasia and prostate cancer.J Urol. 2006 Jun;175(6):2072-7; discussion 2077. doi: 10.1016/S0022-5347(06)00273-4. J Urol. 2006. PMID: 16697805
-
Stromal cells promote angiogenesis and growth of human prostate tumors in a differential reactive stroma (DRS) xenograft model.Cancer Res. 2002 Jun 1;62(11):3298-307. Cancer Res. 2002. PMID: 12036948
-
Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors.Cancer Res. 1999 Oct 15;59(20):5209-18. Cancer Res. 1999. PMID: 10537299
-
Vascular Endothelial FSH Receptor, a Target of Interest for Cancer Therapy.Endocrinology. 2018 Sep 1;159(9):3268-3274. doi: 10.1210/en.2018-00466. Endocrinology. 2018. PMID: 30113652 Review.
-
Expression of follicle stimulating hormone receptors in intra-tumoral vasculature and in tumoral cells - the involvement in tumour progression and the perspectives of application in cancer diagnosis and therapy.Endokrynol Pol. 2018;69(2):192-198. doi: 10.5603/EP.2018.0022. Endokrynol Pol. 2018. PMID: 29952426 Review.
Cited by
-
Follicle-Stimulating Hormone Receptor Is Expressed by Most Ovarian Cancer Subtypes and Is a Safe and Effective Immunotherapeutic Target.Clin Cancer Res. 2017 Jan 15;23(2):441-453. doi: 10.1158/1078-0432.CCR-16-0492. Epub 2016 Jul 19. Clin Cancer Res. 2017. PMID: 27435394 Free PMC article.
-
Controlled ovarian stimulation therapy as a potential risk for the development and progression of renal cell carcinomas: A case report and literature review.Mol Clin Oncol. 2021 Jul;15(1):140. doi: 10.3892/mco.2021.2302. Epub 2021 May 23. Mol Clin Oncol. 2021. PMID: 34094538 Free PMC article.
-
Degarelix as a new antiangiogenic agent for metastatic colon cancer?World J Gastroenterol. 2013 Feb 7;19(5):769-72. doi: 10.3748/wjg.v19.i5.769. World J Gastroenterol. 2013. PMID: 23431078 Free PMC article.
-
Ectopic expression of FSH receptor isoforms in neoplastic but not in endothelial cells from pancreatic neuroendocrine tumors.J Endocrinol Invest. 2013 Mar;36(3):174-9. doi: 10.3275/8472. Epub 2012 Jun 25. J Endocrinol Invest. 2013. PMID: 22732316
-
Anti-Angiogenic Therapy: Albumin-Binding Proteins Could Mediate Mechanisms Underlying the Accumulation of Small Molecule Receptor Tyrosine Kinase Inhibitors in Normal Tissues with Potential Harmful Effects on Health.Diseases. 2021 Apr 10;9(2):28. doi: 10.3390/diseases9020028. Diseases. 2021. PMID: 33920299 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical